Daver, N., Vyas, P., Kambhampati, S., Malki, M., Larson, R., Asch, A., . . . Sallman, D. (2022). AML-464 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML): Phase 1b results. Elsevier.
Citação do estilo Chicago (17ª ed.)Daver, N., et al. AML-464 Tolerability and Efficacy of the First-in-class Anti-CD47 Antibody Magrolimab Combined with Azacitidine in Frontline Patients with TP53-mutated Acute Myeloid Leukemia (AML): Phase 1b Results. Elsevier, 2022.
Citação MLA (9ª ed.)Daver, N., et al. AML-464 Tolerability and Efficacy of the First-in-class Anti-CD47 Antibody Magrolimab Combined with Azacitidine in Frontline Patients with TP53-mutated Acute Myeloid Leukemia (AML): Phase 1b Results. Elsevier, 2022.